Patients who failed to conceive after gonadotropin stimulation in in vitro fertilization treatment were classified into normal, high, or poor responders. They were routinely offered another cycle with a combination of a gonadotropin releasing hormone agonist and gonadotropin therapy (in order to evaluate whether this combined therapy could improve their response). The gonadotropin-induced cycle was compared with the combined therapy cycle. With the combination treatment, in the normal responders the phase of ovarian stimulation was significantly (P<0.001) prolonged, and the number of follicles and oocytes collected (5.7±0.7 vs 3.1±0.4) was increased, without any change in serum estradiol level compared to the control cycle. In high responders the number of oocytes was not modified by the combined treatment compared with the control cycle. However, serum estradiol level was significantly (P<0.005) decreased. The combined therapy did not modify any parameter of response in poor responders. We conclude that the response to combined agonist/gonadotropin therapy is dependent on the patient's own basal response. No improvement in response was expected in poor responders.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Jones HW, Acosta Jr AA, Andrews MC, Garcia JE, Jones GS, Mayer J, McDowell JS, Rosenwaks Z, Sandow BA, Veek LL, Wilkes CA: Three years of in vitro fertilization at Norfolk. Fertil Steril 1984;42:826
Muasher SJ: Stimulation protocols for patients with “atypical response.” In vitro fertilization and other assisted reproduction. NY Acad Sci 1988;541:82–95
Garcia JE, Jones GS, Acosta AA, Wright G Jr: Human menopausal gonadotropin follicular maturation for oocyte aspiration: Phase II 1981. Fertil Steril 1983;39:174–179
Mashiach S, Dor J, Goldenberg M, Shalev J, Blankstein J, Rudak E, Shoam Z, Finelt Z, Nebel L, Goldman B, Ben-Rafael Z: Protocols for induction of ovulation. NY Acad Sci 1988;541:37–45
Fleming R, Haxton MJ, Hamilton MPR, McCune GS, Black WP, MacNaughton MC, Coutts JRT: Successful treatment of infertile women with oligomenorrhea using a combination of LHRH agonist and exogenous gonadotropin. Br J Obstet Gynecol 1985;92:369–973
Fleming R, Coutts JRT: Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril 1986;45:226–230
Frydman R, Furman RG, Belaisch-Allart J, Hazout A, Rainhorn JD, Fries N, Testart J: Improvements in ovarian stimulation for in vitro fertilization. In vitro fertilization and other assisted reproduction. NY Acad Sci 1988;541:30–36
De Ziegler D, Cedars MI, Randle D, Lu JKH, Judd HL, Meldrum DR: Suppression of the ovary using a gonadotropin releasing hormone agonist prior to stimulation for oocyte retrieval. Fertil Steril 1987;48:807–810
Kenigsberg D, Littman BA, Williams RF, Hodgen GD: Medical hypophysectomy. II. Variability of ovarian response to exogenous gonadotropins. Fertil Steril 1984;42:116–126
Serafini P, Stone B, Kerin J, Batzofin J, Quinn J, Marrs RD: An alternate approach to controlled ovarian hyperstimulation in “poor responses”: Pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 1988;49:90–95
Howles CM, MacNamee MC, Edwards RG: Short term use of LHRH agonist to treat poor responders entering in vitro fertilization programme. Hum Reprod 1987;2:655–656
Belaisch-Allart J, Testart J, Frydman R: Utilization of GnRH agonists for poor responders in an IVF programme. Hum Reprod 1989;4:33–34
About this article
Cite this article
Ben-Rafael, Z., Bider, D., Dan, U. et al. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG. J Assist Reprod Genet 8, 33–36 (1991). https://doi.org/10.1007/BF01131588
- gonadotropin releasing hormone (GnRH) analogue
- human menopausal gonadotropin (hMG)
- patient response